Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Fertility-Sparing Treatment for Early Endometrial Cancer
NCT04792749Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of metformin in endometrial cancer (EC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Treatment response rates at 12 months. Status: unknown.
02
Drugs
metformin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04792749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792749.